Resona Asset Management Co. Ltd. Has $7.67 Million Stock Holdings in United Therapeutics Corporation $UTHR

Resona Asset Management Co. Ltd. lowered its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 16.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,282 shares of the biotechnology company’s stock after selling 3,558 shares during the period. Resona Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $7,672,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Geneos Wealth Management Inc. grew its position in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of United Therapeutics by 77.4% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after acquiring an additional 2,655 shares during the last quarter. Park Avenue Securities LLC boosted its stake in shares of United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after purchasing an additional 39 shares in the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of United Therapeutics by 0.7% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 15,580 shares of the biotechnology company’s stock valued at $4,477,000 after purchasing an additional 103 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in United Therapeutics by 17.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company’s stock worth $5,612,000 after purchasing an additional 2,840 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

United Therapeutics stock opened at $473.36 on Tuesday. The stock has a market cap of $20.38 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 2.51 and a beta of 0.84. The firm’s 50-day simple moving average is $487.69 and its 200 day simple moving average is $416.98. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the business posted $6.39 EPS. As a group, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research analyst reports. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Wells Fargo & Company increased their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. HC Wainwright boosted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Finally, Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $429.25, for a total transaction of $9,658,125.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 536,864 shares of company stock valued at $255,191,362 in the last three months. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.